<DOC>
	<DOCNO>NCT01905111</DOCNO>
	<brief_summary>The primary objective trial explore safety tolerability BI 853520 monotherapy determine maximum tolerate dose ( MTD ) Japanese Taiwanese patient advance metastatic solid tumour . Secondary objective collection preliminary data anti-tumour efficacy</brief_summary>
	<brief_title>A Study BI 853520 Japanese Taiwanese Patients With Various Types Advanced Metastatic Cancer</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : Patients confirm diagnosis advance , measurable evaluable , nonresectable and/or metastatic nonhematologic malignancy , show progressive last 6 month Patients fail conventional treatment therapy proven efficacy exist amenable establish treatment option Recovery reversible toxicity ( alopecia exclude ) prior anticancer therapy ( Common Terminology Criteria Adverse Events grade &lt; 2 ) Age &gt; = 20 year Written inform consent accordance International Conference Harmonisation/Good Clinical Practice ( ICH/GCP ) local legislation Eastern Cooperative Oncology Group ( ECOG ) , performance score 01 Exclusion criterion : Serious concomitant nononcological disease/illness Active/symptomatic brain metastasis Second malignancy Pregnancy breastfeed Women men sexually active unwilling use medically acceptable method contraception . Treatment cytotoxic anticancertherapies investigational drug within four week first treatment study medication</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>